Kura Oncology, Inc. (NASDAQ:KURA) Shares Bought by Teacher Retirement System of Texas

Teacher Retirement System of Texas grew its position in Kura Oncology, Inc. (NASDAQ:KURA) by 19.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 13,749 shares of the company’s stock after acquiring an additional 2,285 shares during the period. Teacher Retirement System of Texas’ holdings in Kura Oncology were worth $120,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in the company. E Fund Management Co. Ltd. purchased a new stake in Kura Oncology in the 4th quarter valued at approximately $90,000. Corient Private Wealth LLC acquired a new stake in shares of Kura Oncology in the 4th quarter valued at approximately $109,000. China Universal Asset Management Co. Ltd. boosted its stake in shares of Kura Oncology by 11.9% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 16,489 shares of the company’s stock valued at $144,000 after buying an additional 1,750 shares in the last quarter. Point72 DIFC Ltd acquired a new position in Kura Oncology during the third quarter worth $146,000. Finally, AlphaQuest LLC purchased a new position in Kura Oncology in the fourth quarter worth $177,000.

Insider Buying and Selling

In other Kura Oncology news, SVP Thomas James Doyle sold 4,949 shares of the stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $38,948.63. Following the sale, the senior vice president now directly owns 88,193 shares of the company’s stock, valued at $694,078.91. This trade represents a 5.31 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Mollie Leoni sold 4,963 shares of the company’s stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total transaction of $39,058.81. Following the completion of the transaction, the insider now owns 88,253 shares of the company’s stock, valued at approximately $694,551.11. This trade represents a 5.32 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 11,729 shares of company stock worth $92,307. 5.50% of the stock is currently owned by corporate insiders.

Kura Oncology Price Performance

KURA stock opened at $6.52 on Thursday. The company has a market cap of $526.52 million, a PE ratio of -2.76 and a beta of 0.83. Kura Oncology, Inc. has a 12-month low of $6.27 and a 12-month high of $23.48. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02. The stock has a 50-day moving average price of $7.76 and a two-hundred day moving average price of $11.71.

Kura Oncology (NASDAQ:KURA) last posted its earnings results on Wednesday, February 26th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.43. The company had revenue of $53.88 million during the quarter, compared to analyst estimates of $57.96 million. As a group, research analysts predict that Kura Oncology, Inc. will post -2.44 EPS for the current year.

Analyst Ratings Changes

Several brokerages have commented on KURA. JMP Securities restated a “market outperform” rating and set a $28.00 target price on shares of Kura Oncology in a research report on Thursday, February 6th. Scotiabank decreased their price objective on shares of Kura Oncology from $18.00 to $10.00 and set a “sector perform” rating on the stock in a report on Wednesday, January 8th. Cantor Fitzgerald raised shares of Kura Oncology to a “strong-buy” rating in a report on Tuesday, March 4th. BTIG Research lowered Kura Oncology from a “buy” rating to a “neutral” rating in a research note on Thursday, February 6th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $36.00 price target on shares of Kura Oncology in a report on Thursday, February 27th. Three investment analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, Kura Oncology presently has an average rating of “Moderate Buy” and a consensus price target of $25.50.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.